Symptoms, treatment and costs of patients with benign prostate hyperplasia in ambulatory field;Symptome, Behandlung und Kosten von Patienten mit benigner Prostatahyperplasie im ambulanten Bereich

Urologe - Ausgabe B

Volumn 37, Issue 2, 1997, Pages 123-129

  Pientka, L ^a,b   Gruger J ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AMBULATORY SURGERY; ARTICLE; COST CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY;

EID: 0030955492     PISSN: 00421111     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001310050069     Document Type: Article

References (32)

1. Banta D (ed) (1993) Health care technology and its assessment: an international perspective. Oxford Medical Publishers. Oxford
2. Barnes BA, O'Brien E, Comstock C, D'Arpa DC, Donahue LL (1985) Report on variation in rates of utilization of surgical services in the commonwealth of Massachusetts. JAMA 254: 371-375
3. Berges RR, Windeler J, Trampisch HJ, Senge T and the β-sitosterol Study Group (1995) Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia. Lancet 345: 1529-1532
4. Cockett ATK, Khoury S, Aso Y (1993) The 2nd international consultation on benign prostatic hyperplasia (BPH). Proceedings, Paris
5. Doll HA, Black NA, McPherson KM (1994) Transurethral resection of the prostate for benign prostatic hypertrophy: factors associated with a succesful outcome at 1 year. Br J Urol 73: 669-680
6. Dreikorn K, Richter R, Schönhofer PS (1990) Konservative, nicht-hormonelle Behandlung der bemgnen Prostatahyperplasie. Urologe [A] 29: 8-16
7. Dreikorn K, Schönhofer PS (1995) Stellenwert von Phytotherapeutika bei der Behandlung der benignen Prostatahyperplasie (BPH). Urologe [A] 34: 119-129
8. Drummond MF, McGuire AJ, Black NA, Petticrew M, McPherson CK (1993) Economic burden of treated benign prostatic hyperplasia in the United Kingdom. Br J Urol 71: 290-296
9. Epstein RS (1992) Validation of a new quality of life questionnaire for BPH. J Clin Epidemiol 45:1431-1445
10. Eri LM, Tveter KJ (1995) α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 154: 923-934
11. Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AC, Hanley D (1988) Symptom status an quality of life followine prostatectomy. JAMA 259: 3018-3022
12. Garraway WM, Armstrong C, Auld S, King D, Simpson RJ (1993) Follow-up of a cohort of men with untreated benign prostatic hyperplasia. Eur Urol 24: 313-318
13. Gormley GJ, Stoner E, Bruskewitz RC et al (1992) The effect of finasteride in men with benign prostatic hyperplasia. N EngI J Med 327: 1185-1191
14. Guess HA (1992) Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 14: 131-153
15. Guess HA, Chute CG, Garraway WM et al (1993) Similar levels of urologic symptoms have similar impact of Scotish and American men-although scots report less symptoms. J Urol 150: 1701-1705
16. Issacs JT (1990) Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate [SuppI] 3: 1-8
17. Jardin A, Bensadoun H, Delauche-Cavaluer MC, Stalla-Bourdillon A, Attali P (1994) Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 months survey. Br J Urol 74: 579-584
18. Jønler M, Riehmann M, Bruskewitz RC (1994) Benign prostatic hyperplasia. Drugs 47: 66-81
19. Knopf H-J, Olschewski R, Haupt G, Schulze H, Engelmann U (1991). Symptomatologie und Lebensqualität nach TUR der Prostata - eine prospektive Untersuchung bei 100 Patienten. Akt Urol 22: 99-105
20. Koch E, Biber A (1994) Pharmakologische Wirkungen von Sabal- und Urtikaextrakten als Grundlage für eine rationale medikamentöse Therapie der benignen Prostatahyperplasie. Urologe [B] 34: 90-95
21. Lepor H (1993) Medical therapy for benign prostatic hyperplasia. Urology 42: 483-501
22. McConnell JD, Barry MJ, Bruskewitz RC (1994) Benign prostatic hyperplasia: Diagnosis and treatment. Clinical Practice Guideline, Number 8. AHCPR Publ.-No. 94-0582. Rockville, MD: Agency for Health Care Policy and Research. Public Health Service. U.S. Department of Health and Human Services
23. Oesterling JE (1995) Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med 332: 99-100
24. Pientka L, Grüger J (1993) Benigne Prostatahyperplasie. Klinisch-epidemiologische und ökonomische Aspekte. Münch Med Wochenschr 135: 346-349
25. Pientka L, Van Loghem J, Hahn E, Keil U (1991) Häufigkeit und Komplikationen der Prostataadenomchirurgie bei Patienten mit benigner Prostatahyperplasie. Urologe [B] 31: 211-216
26. Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF, Cohen MM, Ramsey E (1989) Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 320: 1120-1124
27. Schneider H-J (1994) Die Behandlung der benignen Prostatahyperplasie mit Phytopharmaka. Urologe [B] 34: 96-102
28. Schulze H, Berges R, Paschold K, Senge T (1992) Neue konservative Therapieansätze bei der benignen Prostatahyperplasie. Urologe [A] 31: 8-13
29. Scott WG, Scott HM (1993) Annual cost of benign prostatic hyperplasia in New Zealand. PharmacoEcon 4: 455-468
30. Knopf H-J, Olschewski R, Haupt G, Schulze H, Engelmann U (1991). Symptomatologie und Lebensqualität nach TUR der Prostata - eine prospektive Untersuchung bei 100 Patienten. Aktuel Urol 22: 99-105
31. Sejr T, Andersen TF, Madsen M, Roepstorff C, Bilde T, Bay-Nielsen H, Biais R, Holst E (1991) Prostatectomy in Denmark. Scand J Urol Nephrol 25: 101-106
32. Tsang KK, Garraway WM (1994) Prostatism and the burden of benign prostatic hyperplasia on elderly men. Age Ageing 23: 360-364